Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma

Annals of Oncology

Volumn 21, Issue 8, 2010, Pages 1594-1598

  Antoun, S ^a   Baracos, V E ^b   Birdsell, L ^b   Escudier, B ^a   Sawyer, M B ^b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Body mass index; Chemotherapy toxicity; Renal cell carcinoma; Sarcopenia; Sorafenib

Indexed keywords

PLACEBO; SORAFENIB;

ABDOMINAL PAIN; ADULT; ARTICLE; BODY MASS; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG ERUPTION; DRUG WITHDRAWAL; FEMALE; HAND FOOT SYNDROME; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MUSCLE ATROPHY; MUSCLE MASS; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SEX DIFFERENCE;

AGED; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; BODY MASS INDEX; CARCINOMA, RENAL CELL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PYRIDINES; SARCOPENIA;

EID: 77955233464     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp605     Document Type: Article

References (18)

1. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134.
2. Prado CMM, Baracos VE, McCargar LJ et al. Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res 2007; 13: 3264-3268.
3. Prado CMM, Lieffers JR, McCargar LJ et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumors of the respiratory and gastrointestinal tracts: a population based study. Lancet Oncol 2008; 9: 629-635.
4. Akaza H, Tsukamoto T, Murai M et al. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Jpn J Clin Oncol 2007; 37: 755-762.
5. Meyerhardt JA, Tepper JE, Niedzwiecki D et al. Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114. J Clin Oncol 2004; 22: 648-657.
6. Telli ML, Witteles RM, Fisher GA, Srinivas S. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol 2008; 19: 1613-1618.
7. Heymsfield SB, Wang Z, Baumgartner RN, Ross R. Human body composition: advances in models and methods. Annu Rev Nutr 1997; 17: 527-558.
8. Mitsiopoulos N, Baumgartner RN, Heymsfield SB et al. Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. J Appl Physiol 1998; 85: 115-122.
9. Mourtzakis M, Prado CM, Lieffers JR et al. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metabol 2008; 33: 997-1006.
10. Shen W, Punyanitya M, Wang ZM et al. Total body skeletal muscle and adipose tissue volume estimation from a single abdominal cross-sectional image. J Appl Physiol 2004; 97: 2333-2338.
11. Miya T, Goya T, Fujii H et al. Factors affecting the pharmacokinetics of CPT-11: the body mass index, age, and sex are independent predictors of pharmacokinetic parameters of CPT-11. Invest New Drugs 2001; 19: 61-67.
12. Miya T, Goya T, Yanagida O et al. The influence of relative body weight on toxicity of combination chemotherapy with cisplatin and etoposide. Cancer Chemother Pharmacol 1998; 42: 386-390.
13. Renehan AG, Tyson M, Egger M et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008; 16: 569-578.
14. Aslani A, Smith RC, Allen BJ et al. The predictive value of body protein for chemotherapy-induced toxicity. Cancer 2000; 88: 796-803.
15. Prado CMM, Baracos VE, McCargar LJ et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 2009; 15: 2920-2926.
16. Cosquéric G, Sebag A, Ducolombier C et al. Sarcopenia is predictive of nosocomial infection in care of the elderly. Br J Nutr 2006; 96: 895-901.
17. Alexandre J, Goss-Goupil M, Falissard B et al. Evaluation of the nutritional and inflammatory status in cancer patients for the risk assessment of severe haematological toxicity following chemotherapy. Ann Oncol 2003; 14: 36-41.
18. Baumgartner RN, Koehler KM, Gallagher D et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 1998; 147: 755-763.